CorMedix Inc. Common Stock
Financials
Valuation Metrics
CorMedix Inc. Common Stock's Market Cap is $611M. At end of 2025 it was $838M. Ranked #2717 of 3,121 in US market (top 87%), #1172 of 1,463 on NASDAQ (top 80%), #215 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $611M | US#2,717/3,121 Sec#215/266 |
| Revenue | $462M | US#2,297/3,121 Sec#77/266 |
| Net Income | $187M | US#1,322/3,121 Sec#41/266 |
| Total Assets | $904M | US#2,524/3,121 Sec#110/266 |
| Net Assets | $461M | US#2,289/3,121 Sec#117/266 |
| Employees | 191 | US#2,502/3,121 Sec#132/266 |
| Value | ||
| P/E | 3.27x | US#23/3,121 Sec#2/266 |
| P/B | 1.33x | US#717/3,121 Sec#26/266 |
| PEG | 0.01x | US#40/3,121 Sec#5/266 |
| P/S | 1.32x | US#921/3,121 Sec#14/266 |
| EV/EBITDA | 2.00x | US#18/3,121 Sec#3/266 |
| FCF Yield | 41.19% | US#44/3,121 Sec#3/266 |
| Profitability | ||
| ROE | 40.62% | US#165/3,121 Sec#14/266 |
| ROA | 20.70% | US#97/3,121 Sec#14/266 |
| Op. Margin | 46.95% | US#157/3,121 Sec#6/266 |
| Revenue Growth | 280.50% | US#45/3,121 Sec#19/266 |
| Earnings Growth | 265.86% | US#131/3,121 Sec#8/266 |
| Financial Health | ||
| Debt Ratio | 96.18% | US#1,060/3,121 Sec#163/266 |
| Total Debt | $145M | US#2,343/3,121 Sec#104/266 |
| FCF | $252M | US#1,264/3,121 Sec#42/266 |
| Cash | $257M | US#1,546/3,121 Sec#93/266 |
| Current Ratio | 2.56x | US#951/3,121 Sec#202/266 |
| Net Debt/EBITDA | -0.45x | US#410/3,121 Sec#25/266 |
| Performance | ||
| 1Y Return | -29.95% | US#2,622/3,121 Sec#226/266 |
| 1M Return | -4.65% | US#1,652/3,121 Sec#138/266 |
| From 52W High | -40.17% | US#2,468/3,121 Sec#194/266 |
| 1Y MDD | -50.90% | US#2,497/3,121 Sec#184/266 |
| Trading | ||
| Volume | 621,320 shares | US#1,816/3,121 Sec#191/266 |
| Trading Value | $5M | US#2,674/3,121 Sec#223/266 |
| Per Share | ||
| EPS | $2.39 | US#1,222/3,121 Sec#34/266 |
| BPS | $5.87 | US#2,207/3,121 Sec#115/266 |
Company Info
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.